| Title |
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions
|
|---|---|
| Published in |
Cancer Cell International, July 2018
|
| DOI | 10.1186/s12935-018-0594-z |
| Pubmed ID | |
| Authors |
Francesca Battaglin, Madiha Naseem, Alberto Puccini, Heinz-Josef Lenz |
| Abstract |
Gastro-esophageal adenocarcinomas (GEA) represent a severe global health burden and despite improvements in the multimodality treatment of these malignancies the prognosis of patients remains poor. HER2 overexpression/amplification has been the first predictive biomarker approved in clinical practice to guide patient selection for targeted treatment with trastuzumab in advanced gastric and gastro-esophageal junction cancers. More recently, immunotherapy has been approved for the treatment of GEA and PD-L1 expression is now a biomarker required for the administration of pembrolizumab in these diseases. Significant progress has been made in recent years in dissecting the genomic makeup of GEA in order to identify distinct molecular subtypes linked to distinct patterns of molecular alterations. GEA have been found to be highly heterogeneous malignances, representing a challenge for biomarkers discovery and targeted treatment development. The current review focuses on an overview of established and novel promising biomarkers in GEA, covering recent molecular classifications from TCGA and ACRG. Main elements of molecular heterogeneity are discussed, as well as emerging mechanisms of primary and secondary resistance to HER2 targeted treatment and recent biomarker-driven trials. Future perspectives on the role of epigenetics, miRNA/lncRNA and liquid biopsy, and patient-derived xenograft models as a new platform for molecular-targeted drug discovery in GEA are presented. Our knowledge on the genomic landscape of GEA continues to evolve, uncovering the high heterogeneity and deep complexity of these tumors. The availability of new technologies and the identification of promising novel biomarker will be critical to optimize targeted treatment development in a setting where therapeutic options are currently lacking. Nevertheless, clinical validation of novel biomarkers and treatment strategies still represents an issue. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Venezuela, Bolivarian Republic of | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 110 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 20 | 18% |
| Student > Ph. D. Student | 14 | 13% |
| Researcher | 13 | 12% |
| Student > Bachelor | 12 | 11% |
| Other | 8 | 7% |
| Other | 15 | 14% |
| Unknown | 28 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 30% |
| Biochemistry, Genetics and Molecular Biology | 21 | 19% |
| Agricultural and Biological Sciences | 5 | 5% |
| Immunology and Microbiology | 3 | 3% |
| Economics, Econometrics and Finance | 3 | 3% |
| Other | 13 | 12% |
| Unknown | 32 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2019.
All research outputs
#15,539,088
of 23,094,276 outputs
Outputs from Cancer Cell International
#851
of 1,824 outputs
Outputs of similar age
#208,614
of 326,767 outputs
Outputs of similar age from Cancer Cell International
#6
of 20 outputs
Altmetric has tracked 23,094,276 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,824 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,767 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.